Antag Therapeutics raised DKK 20M in funding from Novo Seeds.
Antag Therapeutics ApS, a Copenhagen, Denmark-based biotech startup providing metabolic, anti-obesity treatment solutions announced receiving a €2.7 million ($3 million) investment from Novo Seeds, the early stage investment arm of Novo Holdings A/S.
Antag Therapeutics, led by chairman Kirsten Drejer and CEO Alexander Sparre-Ulrich, is a spinout from the University of Copenhagen and stems from the research groups of Professors Mette M. Rosenkilde and Jens J. Holst.
In collaboration with clinicians from Gentofte and Bispebjerg hospital, the team has discovered a naturally occurring peptide-antagonist of the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and has conducted several human studies with demonstrated effects on fat metabolism.
Antag has been in incubation with Novo Seeds since 2014, and funded through both the exploratory and the pre-seed grant program of the Novo Nordisk Foundation.